Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.

Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.

Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product should be used with caution before heparinization. This product is also suitable for ① trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid glands, and liver; ② used as an antagonist of tissue plasminogen activator (tPA), streptokinase, and urokinase; ③ fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism; ④ menorrhagia, hyphema, and severe epistaxis due to local increased fibrinolysis; ⑤ used to prevent or alleviate tooth extraction or

Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product should be used with caution before heparinization. This product is also suitable for: ① traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid glands, and liver; ② used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; ③ fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism; ④ menorrhagia, hyphema, and severe epistaxis due to local increased fibrinolysis; ⑤ used to prevent or reduce bleeding after tooth extraction or oral surgery in hemophiliacs with factor VIII or factor IX deficiency; ⑥ central artery

Indication: It is mainly used to treat small cell lung cancer, malignant lymphoma, malignant germ cell tumor, leukemia, and has certain therapeutic effects on neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer and esophageal cancer.

Indication: It is suitable for malignant tumors, multiple myeloma, lymphocytic leukemia, neuroblastoma, ovarian cancer, breast cancer, various sarcomas and lung cancer, etc.

Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. This product is generally not used for secondary hyperfibrinolytic state caused by disseminated intravascular coagulation before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Pathologically increased local fibrinolysis in the uterine cavity, menorrhagia, and anterior chamber